BIBenedic Ippolito

Benedic Ippolito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benedic Ippolito has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Batty

    Federal Reserve Board of Governors Washington District of Columbia USA

    3 shared publications
  • Boris Vabson

    Harvard Medical School, Harvard University, Boston, Massachusetts

    2 shared publications
  • Erin Trish

    Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles

    2 shared publications
  • Christa Gibbs

    Christa Gibbs is an economist in the Office of Research, Consumer Financial Protection Bureau, in Washington, D.C.

    1 shared publication
  • Christa N. Gibbs

    Consumer Financial Protection Bureau Washington District of Columbia USA

    1 shared publication
  • Erin L. Duffy

    Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles

    1 shared publication

Latest Publications

  • Open Access

    Contextualizing new estimates of coding intensity in Medicare advantage and opportunities for further research

    by Loren Adler, Yevgeniy Feyman, Benedic Ippolito

    In this piece, we provide context for new estimates of coding intensity in Medicare advantage (MA) and highlight how researchers can build on them to inform ongoing policy debates. In particular, we identify opportunities to study how insurer responses may affect the intended goals of the Center for Medicare and Medicaid Services’s (CMS) recently introduced risk adjustment model, as well as how potential changes in insurer payments may influence plan design.

  • Open Access

    Patient Repayment of US Hospital Bills From 2018 to 2024

    by Benedic Ippolito, Erin Trish, Erin L. Duffy, Boris Vabson

    Importance: Patient cost sharing liability has risen in recent years, increasing the costs associated with care for patient households and imposing collections challenges for hospitals and clinicians.Objective: To measure patient repayment of cost sharing over recent years, and how that varies across patient, hospital, and service characteristics.Design, Setting, and Participants: This cross-sectional study of billing and payment data from a revenue cycle management company examined patient accounts at 217 US hospitals from 2018 to 2024. Participants included 24.5 million and 6.2 million patient episodes of care with positive patient out-of-pocket liability for individuals with private insurance and Medicare Advantage, respectively.Main Outcomes and Measures: Percentage of owed patient cost sharing actually paid among patients with private insurance and Medicare Advantage measured over time, for inpatient and outpatient care and by bill size.Results: Across the full sample of 217 US hospitals (30.7 million patient episodes), mean (SD) patient liability per person, including those with no liability, was higher for individuals with private insurance ($375.41 [$51.55]) than those with Medicare Advantage ($172.50 [$14.84]). Consistent with high-deductible plan design with annual resetting, mean patient liability was higher for visits in January than December, particularly among the privately insured (eg, mean [SD] patient liability for visits among the privately insured in January: $479.44 [$29.21] vs December: $321.63 [$14.29]). Prior to the COVID-19 pandemic (January 2018-February 2020), mean repayment rates were 53.9% and 54.0% for patients with private or Medicare Advantage insurance, respectively, and repayment rates declined in more recent years. Across the entire sample, patients with private or Medicare Advantage insurance paid either 0% or 100% of their owed cost sharing in 92.2% and 94.1% of cases, respectively. Repayment rates varied by bill size with lower repayment rates on the largest bills and the smallest bills, and higher repayment rates on midsized bills.Conclusions and Relevance: This cross-sectional study found that patient cost sharing repayments were incomplete and have fallen in more recent years, which result in both medical debts for patients and collections shortfalls for hospitals and clinicians. These findings suggest that changes to insurance plan design or the treatment of medical debt are among several factors that may contribute to observed results; if declines in cost sharing repayment continue, hospitals and clinicians may increasingly seek payment of cost sharing ahead of service, when allowable.


  • Open Access

    Medicare at a crossroads: A conversation with Dr. Mark McClellan on program reforms and the growth of Medicare Advantage

    by Mark McClellan, Benedic Ippolito

    The Medicare program is rapidly evolving—a reality that presents unique challenges to policymakers. In this conversation, Mark McClellan, the former commissioner of the US Food and Drug Administration and administrator of the Centers for Medicare & Medicaid Services (CMS), offers his perspective on how policy can adapt to the changing environment. He emphasizes several reasons why the Medicare Advantage program's rapid growth in recent years is increasing pressure for reform and how the CMS Innovation Center and other initiatives can play a role in that effort. Among possible reforms, he discusses the prospects of legislation to alter the use of controversial practices by insurers, like prior authorization. Finally, he offers his perspective on what role Traditional Medicare might play in the program's future.


  • Expected Out-Of-Pocket Costs: Comparing Medicare Advantage With Fee-For-Service Medicare

    by Benedic Ippolito, Erin Trish, Boris Vabson

    We compared the generosity of Medicare plans in terms of out-of-pocket costs attributable to cost sharing and premiums, including both basic and supplemental services. From 2014 through 2019, projected out-of-pocket costs for a typical enrollee were 18-24 percent lower in Medicare Advantage than traditional fee-for-service Medicare.


  • Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion

    by Benedic Ippolito, Joseph F. Levy

    The introduction of highly effective anti-obesity drugs, such as Wegovy, has prompted debate over Medicare's prohibition on coverage of such products. In this study, we estimated the costs of allowing Medicare coverage of anti-obesity medications. Our analysis incorporated data on drug costs, real-world adherence rates, and potential changes to other health care spending. Using Medicare claims, we also documented beneficiaries' eligibility for nearly identical products approved for different indications. Assuming that anti-obesity drugs were covered in 2025 and that 5 percent or 10 percent of newly eligible patients were prescribed one, annual Part D costs were estimated to increase by $3.1 billion or $6.1 billion, respectively. The marginal costs of this policy could fall by as much as 62.5 percent from baseline estimates if products were approved for additional indications in coming years because these additional conditions are common among people with obesity. This would increase Medicare spending but would occur regardless of a policy change. Longer-term estimates come with significant uncertainty about utilization and price changes, but these results are consistent with this policy change likely increasing Medicare costs by the low to middle tens of billions of dollars over ten years.


  • Health insurance, medical debt, and financial well‐being

    by Michael Batty, Christa Gibbs, Benedic Ippolito

    We study the financial protection provided by health insurance through two natural experiments—the Affordable Care Act's under 26 provision and Medicare eligibility. In both cases, the coverage expansion sharply reduces medical debt in collections for consumers within the affected ages but does not systematically improve credit outcomes not directly related to medical care. This is consistent with the infrequent repayment rate and lack of persistence on credit reports that we document for medical collections, which mute a key channel through which reductions in medical collections could directly affect the other financial outcomes studied here. These results help clarify the role of health insurance in broader financial health and suggest that, at least among the populations studied here, medical debts in collection may often be a symptom rather than a cause of wider financial distress as measured on credit reports.


  • Unlike Medical Spending, Medical Bills In Collections Decrease With Patients’ Age

    by Michael Batty, Christa Gibbs, Benedic Ippolito

    Health policy is often designed to help protect patients’ financial security. However, there is limited understanding of the role medical debt plays in household finances. We used credit report data on more than four million Americans to study the age profile of people whose medical bills were sent to a US collections agency in 2016. We found that, unlike health care use and spending, medical collections decreased substantially with age. The average size of medical debt decreased nearly 40 percent from patients age twenty-seven to sixty-four, with increases in health insurance coverage and incomes likely playing important mediating roles. However, the frequency of medical collections—that is, the proportion of people with a collection by age—was less closely tied to insurance coverage rates. A potential explanation is that most medical collections were relatively modest in size, with more than half of them less than $600 annually. As a result, medical collections could still occur under typical insurance ...


  • Mystery Of The Chargemaster: Examining The Role Of Hospital List Prices In What Patients Actually Pay

    by Michael Batty, Benedic Ippolito

    Hospitals in the United States maintain chargemasters that contain the official list prices for all billable services. The prices vary widely across hospitals and are more than three times what hospitals are paid for treating a patient, on average. From this it is tempting to conclude that list prices are a strange, yet ultimately inconsequential, quirk of US health care. However, using both state and national data sets covering the period 2002–14, we found considerable evidence suggesting that list prices reflect hospitals’ strategic behavior and have meaningful effects on payments made by and on behalf of patients. Specifically, we found that list prices varied predominantly across hospitals and within markets, were well predicted by observable hospital characteristics, and were positively related to prices actually paid by patients and their insurers. Moreover, analyses of data before and after the implementation of California’s Hospital Fair Pricing Act suggest that high list prices causally increased payments from the uninsured. However, list prices had at most a limited relationship with care quality.